Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trialKazumoto Iijima, Yasuo Ohashi, Mayumi Sako et al.|The Lancet|2014Cited by 450
A multicenter randomized trial indicates initial prednisolone treatment for childhood nephrotic syndrome for two months is not inferior to six-month treatmentNorishige Yoshikawa, Kazumoto Iijima, Hiroshi Hataya et al.|Kidney International|2014Cited by 135
Mycophenolate Mofetil after Rituximab for Childhood-Onset Complicated Frequently-Relapsing or Steroid-Dependent Nephrotic SyndromeKazumoto Iijima, Mayumi Sako, Mari S. Oba et al.|Institutional Repositories DataBase (IRDB)|2022Cited by 57
Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximabKazumoto Iijima, Koichi Kamei, Kenji Ishikura et al.|Pediatric Nephrology|2017Cited by 54
Cyclosporine C2 Monitoring for the Treatment of Frequently Relapsing Nephrotic Syndrome in ChildrenKazumoto Iijima, Norishige Yoshikawa, Mayumi Sako et al.|Clinical Journal of the American Society of Nephrology|2013Cited by 32